| P50 | author | Hideki Ohdan | Q90330341 |
| | Takao Hinoi | Q96950096 |
| | Hiroyuki Egi | Q114861104 |
| | Manabu Shimomura | Q115940703 |
| | Tomohiro Adachi | Q115940794 |
| P2093 | author name string | Yasuyo Ishizaki | |
| | Minoru Hattori | |
| | Shoichiro Mukai | |
| | Masashi Miguchi | |
| | Hiroyuki Sawada | |
| | Hiroaki Niitsu | |
| | Yasufumi Saito | |
| | Masatoshi Kochi | |
| P2860 | cites work | Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 |
| | The role of primary tumour resection in patients with stage IV colorectal cancer | Q33284711 |
| | The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. | Q35065408 |
| | Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. | Q35332617 |
| | Incurable colorectal carcinoma: the role of surgical palliation | Q35780278 |
| | Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. | Q36212412 |
| | Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy | Q36775133 |
| | Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. | Q36822171 |
| | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. | Q37946252 |
| | Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis | Q38027392 |
| | Current opinion on optimal treatment for colorectal cancer. | Q38101612 |
| | Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). | Q38176601 |
| | Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer | Q39414140 |
| | KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial | Q43250046 |
| | A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival | Q43547700 |
| | Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone | Q44076972 |
| | Operation in patients with incurable colon cancer--is it worthwhile? | Q46114082 |
| | Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601. | Q46152911 |
| | A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. | Q46755325 |
| | Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. | Q51721033 |
| | Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. | Q54591533 |
| | Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. | Q54709996 |
| | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making | Q57758061 |
| | Palliation for rectal cancer. Resection? Anastomosis? | Q68993283 |
| | Palliative resection for colorectal carcinoma | Q72641098 |
| | Non-curative surgery for colorectal cancer: critical appraisal of outcomes | Q79294875 |
| | Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? | Q79356459 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | colorectal cancer | Q188874 |
| | chemotherapy | Q974135 |
| P304 | page(s) | 162 | |
| P577 | publication date | 2015-04-24 | |
| P1433 | published in | World Journal of Surgical Oncology | Q14520241 |
| P1476 | title | Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases | |
| P478 | volume | 13 | |